• NKGen Biotech amended its secured convertible loan agreement with AlpineBrook Capital GP I, adding a USD 412,500 loan that includes a USD 37,500 facilitation fee.
• Net proceeds were USD 375,000, documented through a new Secured Convertible Promissory Note (Additional Note #2) convertible at USD 0.08 per share, subject to adjustment.
• The amendment increased consideration shares owed to the lender to 12,147,280, scheduled for delivery in five installments over 25 months from the loan agreement closing.
• A new Common Stock Purchase Warrant (Additional Warrant #2) allows purchases at USD 0.08 per share for a 10-year term, with a 9.99% beneficial ownership cap.
• A voting agreement commits key holders to support an increase in authorized common shares to cover the consideration shares and potential share issuance tied to the notes and warrants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-060160), on May 21, 2026, and is solely responsible for the information contained therein.